Table 4 Summary of recommendations

Recommendation 1:

We suggest using tixagevimab + cilgavimab for prophylaxis in people at high risk of developing severe COVID-19 (conditional recommendation, very low certainty in evidence)

Recommendation 2:

We suggest using tixagevimab + cilgavimab in outpatients with mild COVID-19 (conditional recommendation, moderate certainty in evidence)

Recommendation 3.1:

We suggest against using molnupiravir in outpatients with mild COVID-19 and no risk factors for severe disease (conditional recommendation, very low certainty in evidence)

Recommendation 3.2:

We suggest using molnupiravir in outpatients with mild COVID-19 and risk factors for severe disease (conditional recommendation, very low certainty in evidence)

Recommendation 4:

We recommend using nirmatrelvir/ritonavir in outpatients with mild COVID-19 (strong recommendation, moderate certainty in evidence)

Recommendation 5:

We suggest using remdesivir in outpatients with mild COVID-19 (conditional recommendation, low certainty in evidence)

Recommendation 6:

We recommend against using hydroxychloroquine or chloroquine in outpatients with mild COVID-19 (strong recommendation, moderate certainty in evidence)

Recommendation 7:

We recommend against using ivermectin in outpatients with mild COVID-19 (strong recommendation, moderate certainty in evidence)

Recommendation 8:

We suggest using remdesivir in hospitalised patients with severe COVID-19 (conditional recommendation, low certainty in evidence)

Recommendation 9:

We suggest using baricitinib in hospitalised patients with severe COVID-19 (conditional recommendation, moderate certainty in evidence)

Recommendation 10:

We suggest using tocilizumab in hospitalised patients with severe COVID-19 (conditional recommendation, moderate certainty in evidence)